Answers are grounded in this paper and cite their sources.
In vitro analysis of MET H1094Y and F1200I mutations in PC9 cells. (A) Establishment of NSCLC cancer cell lines expressing MET TKD mutations. PC9 cells were transduced with wild-type (WT) MET (as control) and MET H1094Y and F1200I. (B) Growth inhibition assay of PC9 cells in response to EGFR inhibition with osimertinib. (C) Cell proliferation and relative apoptosis were monitored under EGFR inhibition with osimertinib (300 nM). (D) Phosphorylation of MET, EGFR, AKT, and ERK was analyzed in PC9 cells expressing MET TKD mutants. PC9 cells were treated with osimertinib (1 μM) with or without capmatinib (1 μM) for 48 hrs. (E) IC50 values of PC9 cells (upper table) and Ba/F3 cells (lower table) expressing MET TKD mutants in response to MET TKIs. PC9 cells were treated with gradient dose of MET TKI combined with a fixed dose of osimertinib (100 nM) for 72 hrs.
No takes yet. Share an insight, caveat, or question.
Pecci et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: